Amarin names Paul Huff chief commercial officer
This article was originally published in Scrip
Executive Summary
Paul Huff has been appointed chief commercial officer at Amarin, a clinical-stage biopharmaceutical company focused on cardiovascular disease. He will be responsible for driving the commercialisation of the company's lead product candidate, AMR101, and will also provide business development support as the Amarin evaluates potential strategic partnerships for the commercialisation of AMR101. Mr Huff has more than 25 years' cardiovascular-focused pharmaceutical marketing and sales experience, having previously held sales and marketing positions at a number of companies, including Reliant Pharmaceuticals and Kos Pharmaceuticals.